Targeting Jak3 for immune suppression and allograft acceptance.
Kirken
R A
RA
Department of Integrative Biology and Pharmacology; University of Texas-Houston, Texas 77030, USA.
D000938:Antigen-Presenting Cells / Q000276:immunology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D053616:Janus Kinase 3; D018448:Models, Immunological; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology / Q000502:physiology*
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3